A detailed history of Acadian Asset Management LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 2,851 shares of PMCB stock, worth $4,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,851
Previous 2,851 -0.0%
Holding current value
$4,476
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$1.95 - $2.52 $1,439 - $1,859
-738 Reduced 20.56%
2,851 $5,000
Q1 2024

May 10, 2024

SELL
$1.95 - $2.48 $2,340 - $2,976
-1,200 Reduced 25.06%
3,589 $8,000
Q4 2023

Feb 13, 2024

SELL
$2.01 - $2.34 $4,697 - $5,468
-2,337 Reduced 32.8%
4,789 $10,000
Q2 2023

Aug 07, 2023

SELL
$2.74 - $3.18 $5,858 - $6,798
-2,138 Reduced 23.08%
7,126 $20,000
Q1 2023

May 11, 2023

BUY
$2.83 - $3.03 $26,217 - $28,069
9,264 New
9,264 $26,000

Others Institutions Holding PMCB

About PharmaCyte Biotech, Inc.


  • Ticker PMCB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,750,100
  • Market Cap $32.6M
  • Description
  • PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...
More about PMCB
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.